Nymox Pharmaceutical Balance Sheet Health
Financial Health criteria checks 1/6
Nymox Pharmaceutical has a total shareholder equity of $-1.9M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $669.0K and $2.6M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
Interest coverage ratio | n/a |
Cash | US$76.00k |
Equity | -US$1.90m |
Total liabilities | US$2.57m |
Total assets | US$669.00k |
Recent financial health updates
Recent updates
Nymox gets FDA feedback on NDA resubmission for lead asset
Sep 13Is Nymox Pharmaceutical (NASDAQ:NYMX) In A Good Position To Deliver On Growth Plans?
Aug 17NYMOX stock down 7.2% after receiving non-compliance letter from Nasdaq
Jul 14Nymox to file for Fexapotide approval by mid-September
May 06Nymox under pressure on $8M private placement
Apr 28What You Need To Know About Nymox Pharmaceutical Corporation's (NASDAQ:NYMX) Investor Composition
Mar 01Financial Position Analysis
Short Term Liabilities: NYMX.F has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: NYMX.F has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: NYMX.F is debt free.
Reducing Debt: NYMX.F's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NYMX.F has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: NYMX.F has less than a year of cash runway if free cash flow continues to grow at historical rates of 2.8% each year.